vTv Therapeutics Reports Q2 2025 Results, Phase 3 CATT1 Trial Begins

• vTv Therapeutics reports Q2 2025 financial results • First participant randomized in Phase 3 CATT1 trial for cadisegliatin • Cadisegliatin IP portfolio expanded • Leadership team strengthened • Data expected in H2 2026 • vTv Therapeutics focused on oral adjunctive therapy for T1D

vTv Therapeutics, Inc. (VTVT) has released its Q2 2025 financial results, highlighting significant developments in its pipeline and strategic initiatives. The company reported that the first participant has been randomized in the Phase 3 CATT1 trial for cadisegliatin, a promising oral adjunctive therapy for Type 1 Diabetes (T1D).

Financial Highlights

vTv Therapeutics reported a net loss of $0.333 million for Q2 2025, an increase from the net loss of $0.025 million in Q1 2025. The company attributed this increase to the reclassification of the NCI net loss to permanent equity on February 27, 2024 [1].

Clinical Milestones

One of the most notable achievements during the quarter was the initiation of the Phase 3 CATT1 trial for cadisegliatin. This trial marks a significant step forward in the company's efforts to develop effective oral adjunctive therapies for T1D. The company expects to release data from this trial in H2 2026.

Portfolio Expansion

vTv Therapeutics also announced the expansion of its intellectual property (IP) portfolio for cadisegliatin. This expansion includes new collaborations and agreements that aim to strengthen the company's position in the T1D market.

Leadership Team

The company has further bolstered its leadership team with strategic hires, aiming to accelerate its clinical and commercial development efforts. This move underscores vTv Therapeutics' commitment to driving innovation and growth in the T1D treatment landscape.

Future Outlook

Looking ahead, vTv Therapeutics is focused on delivering robust clinical data and securing regulatory approvals for cadisegliatin. The company's strategic initiatives, including its leadership team expansion and IP portfolio growth, position it well for future success.

References

[1] https://www.stocktitan.net/sec-filings/VTVT/10-q-v-tv-therapeutics-inc-quarterly-earnings-report-944bab78b83d.html